中國(guó)抗擊新型冠狀病毒的策略與進(jìn)展
發(fā)布時(shí)間:2022-01-20 16:14
新型冠狀病毒肺炎(COVID-19)是21世紀(jì)第三次由冠狀病毒引發(fā)的流行病,并導(dǎo)致全球大規(guī)模感染和死亡,造成全球性公共衛(wèi)生事件。基于在防控重癥急性呼吸綜合征(SARS)和中東呼吸綜合征(MERS)兩次疫情中積累的經(jīng)驗(yàn),中國(guó)迅速確定病毒傳播途徑,總結(jié)臨床特點(diǎn),提出治療干預(yù)措施并開展疫苗研發(fā),在科學(xué)界發(fā)揮了關(guān)鍵作用。盡管針對(duì)COVID-19的研究取得了快速進(jìn)展,但在追溯病毒起源、明確傳播途徑和解析致病機(jī)制等方面仍有待進(jìn)一步研究。目前仍需建立更具針對(duì)性的臨床治療方案以及研發(fā)特效藥。本文總結(jié)了中國(guó)針對(duì)COVID-19防控的主要策略及研究進(jìn)展,以期為全球疫情防控提供有用的信息。
【文章來源】:Engineering. 2020,6(10)EISCI
【文章頁數(shù)】:20 頁
【文章目錄】:
1. Introduction
2. Overview of the strategies for battling against COVID-19 in China
3. Possible mechanisms underlying viral infection
4. Transmission routes
5. Advances in laboratory diagnosis
6. Clinical characteristics of COVID-19
7. Prognostic prediction of critical illnesses
8. Advances in clinical management
9. Vaccine development
1 0. Summary
1.引言
2.中國(guó)抗擊COVID-19的策略概述
3.SARS-Co V-2的感染機(jī)制
4.傳播途徑
5.實(shí)驗(yàn)室診斷的進(jìn)展
6.COVID-19的臨床特點(diǎn)
7.危重癥患者的預(yù)后預(yù)測(cè)
8.臨床治療進(jìn)展
9.疫苗研發(fā)
10.結(jié)語
【參考文獻(xiàn)】:
期刊論文
[1]Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19[J]. Jing-Chun Song,Gang Wang,Wei Zhang,Yang Zhang,Wei-Qin Li,Zhou Zhou. Military Medical Research. 2020(04)
[2]Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19[J]. Mingxing Huang,Man Li,Fei Xiao,Pengfei Pang,Jiabi Liang,Tiantian Tang,Shaoxuan Liu,Binghui Chen,Jingxian Shu,Yingying You,Yang Li,Meiwen Tang,Jianhui Zhou,Guanmin Jiang,Jingfen Xiang,Wenxin Hong,Songmei He,Zhaoqin Wang,Jianhua Feng,Changqing Lin,Yinong Ye,Zhilong Wu,Yaocai Li,Bei Zhong,Ruilin Sun,Zhongsi Hong,Jing Liu,Huili Chen,Xiaohua Wang,Zhonghe Li,Duanqing Pei,Lin Tian,Jinyu Xia,Shanping Jiang,Nanshan Zhong,Hong Shan. National Science Review. 2020(09)
[3]基于CRISPR/Cas12a的可視熒光法快速靈敏檢測(cè)新型冠狀病毒(英文)[J]. 王鑫杰,鐘名天,劉勇,馬培祥,黨露,孟慶洲,萬聞蔚,馬曉冬,劉佳,楊光,楊子峰,黃行許,劉明. Science Bulletin. 2020(17)
[4]血必凈注射液對(duì)重型新型冠狀病毒肺炎患者炎癥指標(biāo)及病情轉(zhuǎn)歸的療效觀察[J]. 文隆,周志國(guó),姜迪譞,黃康. 中華危重病急救醫(yī)學(xué). 2020(04)
本文編號(hào):3599136
【文章來源】:Engineering. 2020,6(10)EISCI
【文章頁數(shù)】:20 頁
【文章目錄】:
1. Introduction
2. Overview of the strategies for battling against COVID-19 in China
3. Possible mechanisms underlying viral infection
4. Transmission routes
5. Advances in laboratory diagnosis
6. Clinical characteristics of COVID-19
7. Prognostic prediction of critical illnesses
8. Advances in clinical management
9. Vaccine development
1 0. Summary
1.引言
2.中國(guó)抗擊COVID-19的策略概述
3.SARS-Co V-2的感染機(jī)制
4.傳播途徑
5.實(shí)驗(yàn)室診斷的進(jìn)展
6.COVID-19的臨床特點(diǎn)
7.危重癥患者的預(yù)后預(yù)測(cè)
8.臨床治療進(jìn)展
9.疫苗研發(fā)
10.結(jié)語
【參考文獻(xiàn)】:
期刊論文
[1]Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19[J]. Jing-Chun Song,Gang Wang,Wei Zhang,Yang Zhang,Wei-Qin Li,Zhou Zhou. Military Medical Research. 2020(04)
[2]Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19[J]. Mingxing Huang,Man Li,Fei Xiao,Pengfei Pang,Jiabi Liang,Tiantian Tang,Shaoxuan Liu,Binghui Chen,Jingxian Shu,Yingying You,Yang Li,Meiwen Tang,Jianhui Zhou,Guanmin Jiang,Jingfen Xiang,Wenxin Hong,Songmei He,Zhaoqin Wang,Jianhua Feng,Changqing Lin,Yinong Ye,Zhilong Wu,Yaocai Li,Bei Zhong,Ruilin Sun,Zhongsi Hong,Jing Liu,Huili Chen,Xiaohua Wang,Zhonghe Li,Duanqing Pei,Lin Tian,Jinyu Xia,Shanping Jiang,Nanshan Zhong,Hong Shan. National Science Review. 2020(09)
[3]基于CRISPR/Cas12a的可視熒光法快速靈敏檢測(cè)新型冠狀病毒(英文)[J]. 王鑫杰,鐘名天,劉勇,馬培祥,黨露,孟慶洲,萬聞蔚,馬曉冬,劉佳,楊光,楊子峰,黃行許,劉明. Science Bulletin. 2020(17)
[4]血必凈注射液對(duì)重型新型冠狀病毒肺炎患者炎癥指標(biāo)及病情轉(zhuǎn)歸的療效觀察[J]. 文隆,周志國(guó),姜迪譞,黃康. 中華危重病急救醫(yī)學(xué). 2020(04)
本文編號(hào):3599136
本文鏈接:http://sikaile.net/yixuelunwen/liuxingb/3599136.html
最近更新
教材專著